March-In Mayhem 🥾

Last week, the White House announced it has plans to use the government’s “March-in” rights on drugs developed with public funding. 

This week, we’re joined by our very own Executive Director here at Patients Rising, MacKay Jimeson. He explains why he and other experts believe this will not lower what patients pay at the counter for prescriptions, and actually could do much more damage by discouraging new treatment development, particularly for the rare disease patient community. 

We also talk about the FDA approval of a powerful new tool that will treat sickle cell disease.

Need help?

The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at the Patients Rising Helpline.

Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?

Drop us a line: [email protected]

The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising, nor do the views and opinions stated on this show reflect the opinions of a guest’s current or previous employers.